← Back to Clinical Trials
Recruiting NCT07526766

NCT07526766 A Study Of Exercise In Patients With Spontaneous Coronary Artery Dissection And Fibromuscular Dysplasia

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07526766
Status Recruiting
Phase
Sponsor Mayo Clinic
Condition Fibromuscular Dysplasia
Study Type INTERVENTIONAL
Enrollment 28 participants
Start Date 2026-09-11
Primary Completion 2027-08-30

Eligibility & Interventions

Sex All sexes
Min Age 21 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
Aerobic and resistance exercises

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 28 participants in total. It began in 2026-09-11 with a primary completion date of 2027-08-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to assess the cardiopulmonary, hemodynamic, and symptom responses to acute bouts of varying intensity aerobic and resistance exercise in people with Spontaneous Coronary Artery Dissection (SCAD) and/or Fibromuscular Dysplasia (FMD).

Eligibility Criteria

Inclusion criteria: * History of Spontaneous Coronary Artery Dissection (SCAD) and/or Fibromuscular Dysplasia (FMD), ≥2 months post-event, and free from chest pain. * Able to provide written informed consent Exclusion criteria: * Individuals who are clinically obese (BMI ≥36) and/or who suffer from musculoskeletal or other conditions that would limit exercise participation. * Individuals who are deemed medically unstable * Participants who are unable to comply with study requirements. * Pregnancy

Contact & Investigator

Central Contact

Armia R. Habil, MD

✉ habil.armia@mayo.edu

📞 904-953-0859

Principal Investigator

Elizabeth H. Dineen, DO

PRINCIPAL INVESTIGATOR

Mayo Clinic

Frequently Asked Questions

Who can join the NCT07526766 clinical trial?

This trial is open to participants of all sexes, aged 21 Years or older, up to 65 Years, studying Fibromuscular Dysplasia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07526766 currently recruiting?

Yes, NCT07526766 is actively recruiting participants. Contact the research team at habil.armia@mayo.edu for enrollment information.

Where is the NCT07526766 trial being conducted?

This trial is being conducted at Jacksonville, United States.

Who is sponsoring the NCT07526766 clinical trial?

NCT07526766 is sponsored by Mayo Clinic. The principal investigator is Elizabeth H. Dineen, DO at Mayo Clinic. The trial plans to enroll 28 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology